The DREAMM-7 study (NCT04246047) compared the efficacy and safety of belantamab mafodotin (BVd) versus daratumumab (DVd) in relapsed/refractory multiple myeloma (MM) patients who had received at least one prior line of therapy. BVd demonstrated superior progression-free survival (PFS) with a median of 36.6 months compared to 13.4 months for DVd. BVd also exhibited higher rates of complete response or better and minimal residual disease (MRD) negativity, along with a longer median duration of response (DOR) of 35.6 months versus 17.8 months with DVd.

Key Points:

• BVd significantly extended median PFS compared to DVd in relapsed/refractory MM.
• BVd demonstrated higher rates of complete response and MRD negativity.
• BVd showed a longer median duration of response compared to DVd.
• Early data suggests a potential overall survival (OS) benefit with BVd, with updated results anticipated to influence clinical practice.

Authors:

Vania Hungria, MD, PhD, Pawel Robak, MD, PhD, Marek Hus, MD, PhD, Vera Zherebtsova, MD, Christopher Ward, MD, PhD, Phoebe Joy Ho, MBBS, Roman Hajek, MD, PhD, Kihyun Kim, MD, Sebastian Grosicki, MD, PhD, Hanlon Sia, MBBS FRACP FRCPA, Adam Bryant, MBBS(Hon), PhD, FRACP, FRCPA, Marcelo Pitombeira de Lacerda, MD, PhD, Gracia Aparecida Martinez, MD, PhD, Anna Maria Sureda Balarí, MD, PhD, Irwindeep Sandhu, MD, Claudio Cerchione, MD, Peter Ganly, BMBCh, PhD, Meletios Dimopoulos, MD, Chengcheng Fu, Mamta Garg, MD, Al-Ola Abdallah, MD, Moshe E Gatt, MD, Albert Oriol, MD, Michele Cavo, MD, Robert Rifkin, MD, FACP, Tomoaki Fujisaki, MD, PhD, Michał Mielnik, MD, Nick Pirooz, MHA, Joe Lee, PhD, Astrid McKeown, PhD, Rachel Rogers, MS*, Hena Baig, BS, Lydia Eccersley, MBBS, MRCP, FRCPath, PhD, Sumita Roy-Ghanta, MD and Maria Victoria Mateos, MD, PhD